Mateusz T. Wasylewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Mateusz T. Wasylewski has a total of 114 co-authors. Here are the top co-authors by number of shared publications:
- Marcin Waligora
Affiliation Faculty of Health Sciences, Research Ethics in Medicine Study Group (REMEDY), Jagiellonian University Medical College, Krakow, Poland
8 shared publications - Karolina Strzebonska
Research Ethics in Medicine Study Group (REMEDY), Jagiellonian University Medical College, Krakow, Poland
6 shared publications - Elżbieta Anita Bajcar
Pain Research Group, Institute of Psychology, Jagiellonian University, Kraków, Poland
3 shared publications - Giuliana Mazzoni
Department of Dynamic and Clinical Psychology, and Health Studies La Sapienza University of Rome Rome Italy
3 shared publications - Przemysław Bąbel
Pain Research Group, Institute of Psychology Jagiellonian University Kraków Poland
3 shared publications - Stefanie Helena Meeuwis
Center of Research on Psychological disorders and Somatic diseases (CoRPS), Department of Medical and Clinical Psychology, Tilburg School of Social and Behavioral Sciences, Tilburg University, Tilburg, the Netherlands
3 shared publications
Latest Publications
- Open Access
- 3 April 2026
- Published by Center for Open Science in MetaArXiv
COmplete Reporting for Transparent Reproducibility Efforts (CORTRE): a reporting guideline [Stage 1 Registered Report]
Concerns about the lack of reproducibility of research have led to numerous investigations across disciplines to quantify the problem. Reproducibility efforts are projects that systematically re-examine previously published findings or previously tested hypotheses. These efforts have played an important role in shaping debates about research credibility, methodological rigour and the incentive structures in academia. Despite the impact of these efforts on science policy (e.g. journal and funder policies), their reporting practices vary. Prior research has shown that many previously published reproducibility efforts do not clearly define the type of reproducibility they are investigating, explain the reasoning for their choice of reproduction success criteria, or explain their approach to the synthesis of results across the included studies. Incomplete reporting hinders interpretation, comparison across efforts and disciplines, and limits opportunities for reanalysis and informing policy. For this reason, the CORTRE project aims to develop a consensus-based reporting guideline for reproducibility efforts. Here, we build on preparatory work identifying a preliminary list of reporting items, based on which we plan to conduct an online, modified Delphi study. Our Delphi panel will be composed of an international and interdisciplinary group of experts with documented experience in designing, conducting, reanalysing, reviewing, publishing or funding reproducibility efforts. After completion of the Delphi exercise, a hybrid consensus meeting will finalise the reporting guideline. This phase 1 registered report details our rationale, methodological approach and the analysis plan for the Delphi exercise.
- 3 April 2026
- Published by Center for Open Science in MetaArXiv
Open AccessCOmplete Reporting for Transparent Reproducibility Efforts (CORTRE): a reporting guideline [Stage 1 Registered Report]
Concerns about the lack of reproducibility of research have led to numerous investigations across disciplines to quantify the problem. Reproducibility efforts are projects that systematically re-examine previously published findings or previously tested hypotheses. These efforts have played an important role in shaping debates about research credibility, methodological rigour and the incentive structures in academia. Despite the impact of these efforts on science policy (e.g. journal and funder policies), their reporting practices vary. Prior research has shown that many previously published reproducibility efforts do not clearly define the type of reproducibility they are investigating, explain the reasoning for their choice of reproduction success criteria, or explain their approach to the synthesis of results across the included studies. Incomplete reporting hinders interpretation, comparison across efforts and disciplines, and limits opportunities for reanalysis and informing policy. For this reason, the CORTRE project aims to develop a consensus-based reporting guideline for reproducibility efforts. Here, we build on preparatory work identifying a preliminary list of reporting items, based on which we plan to conduct an online, modified Delphi study. Our Delphi panel will be composed of an international and interdisciplinary group of experts with documented experience in designing, conducting, reanalysing, reviewing, publishing or funding reproducibility efforts. After completion of the Delphi exercise, a hybrid consensus meeting will finalise the reporting guideline. This phase 1 registered report details our rationale, methodological approach and the analysis plan for the Delphi exercise.
- Open Access
- 1 February 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 181, 111710
Results reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed
- 1 February 2025
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 181, 111710
Open AccessResults reporting for clinical trials led by medical universities and university hospitals in the nordic countries was often missing or delayed
- Open Access
- 16 June 2024
- Published by Oxford University Press (OUP) in Journal of Deaf Studies and Deaf Education
- Vol. 29 (4) , 443-455
Ethics of research engagement with Deaf people. A qualitative evidence synthesis
In this article, we explore ethical issues of Deaf people’s engagement in research. To focus on the perspectives of Deaf people, we investigated existing qualitative and mixed methods research within a qualitative evidence synthesis. Our synthesis is based on a systematic database search (Scopus, PubMed) and reference check of included papers which resulted in 27 eligible papers. We analyzed the data using thematic synthesis and developed 5 analytical themes. The results present research as a struggle for Deaf people and emphasize the need for changes regarding recognition of Deaf research in a cross-cultural context, maintaining equal and partner relations, and provision of accessible communication. Our research contributes to understanding what the ethical inclusion of Deaf people in research implies. It may also support the development of evidence-based normative recommendations and scientific cooperation between Deaf and hearing people.
- 16 June 2024
- Published by Oxford University Press (OUP) in Journal of Deaf Studies and Deaf Education
- Vol. 29 (4) , 443-455
Open AccessEthics of research engagement with Deaf people. A qualitative evidence synthesis
In this article, we explore ethical issues of Deaf people’s engagement in research. To focus on the perspectives of Deaf people, we investigated existing qualitative and mixed methods research within a qualitative evidence synthesis. Our synthesis is based on a systematic database search (Scopus, PubMed) and reference check of included papers which resulted in 27 eligible papers. We analyzed the data using thematic synthesis and developed 5 analytical themes. The results present research as a struggle for Deaf people and emphasize the need for changes regarding recognition of Deaf research in a cross-cultural context, maintaining equal and partner relations, and provision of accessible communication. Our research contributes to understanding what the ethical inclusion of Deaf people in research implies. It may also support the development of evidence-based normative recommendations and scientific cooperation between Deaf and hearing people.
- Open Access
- 15 June 2023
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (11) , 2383-2396
Learning pain from others: a systematic review and meta-analysis of studies on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning
Observing someone experience pain relief or exacerbation after an intervention may induce placebo hypoalgesia or nocebo hyperalgesia. Understanding the factors that contribute to these effects could help in the development of strategies for optimizing treatment of chronic pain conditions. We systematically reviewed and meta-analyzed the literature on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning (OL). A systematic literature search was conducted in the databases PubMed, PsycINFO, Web of Science, ScienceDirect, PsycARTICLES, Scopus, and Academic Search Ultimate. Twenty-one studies were included in the systematic review, 17 of which were suitable for meta-analysis (18 experiments; n = 764 healthy individuals). The primary end point was the standardized mean difference (SMD) for pain following placebo cues associated during OL with low vs high pain. Observational learning had a small-to-medium effect on pain ratings (SMD 0.44; 95% confidence interval [CI] 0.21-0.68; P < 0.01) and a large effect on pain expectancy (SMD 1.11; 95% CI 0.49-2.04; P < 0.01). The type of observation (in-person vs videotaped) modulated the magnitude of placebo hypoalgesia/nocebo hyperalgesia ( P < 0.01), whereas placebo type did not ( P = 0.23). Finally, OL was more effective when observers' empathic concern (but no other empathy-related factors) was higher ( r = 0.14; 95% CI 0.01-0.27; P = 0.03). Overall, the meta-analysis demonstrates that OL can shape placebo hypoalgesia and nocebo hyperalgesia. More research is needed to identify predictors of these effects and to study them in clinical populations. In the future, OL could be an important tool to help maximize placebo hypoalgesia in clinical settings.
- 15 June 2023
- Published by Wolters Kluwer Health in Pain
- Vol. 164 (11) , 2383-2396
Open AccessLearning pain from others: a systematic review and meta-analysis of studies on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning
Observing someone experience pain relief or exacerbation after an intervention may induce placebo hypoalgesia or nocebo hyperalgesia. Understanding the factors that contribute to these effects could help in the development of strategies for optimizing treatment of chronic pain conditions. We systematically reviewed and meta-analyzed the literature on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning (OL). A systematic literature search was conducted in the databases PubMed, PsycINFO, Web of Science, ScienceDirect, PsycARTICLES, Scopus, and Academic Search Ultimate. Twenty-one studies were included in the systematic review, 17 of which were suitable for meta-analysis (18 experiments; n = 764 healthy individuals). The primary end point was the standardized mean difference (SMD) for pain following placebo cues associated during OL with low vs high pain. Observational learning had a small-to-medium effect on pain ratings (SMD 0.44; 95% confidence interval [CI] 0.21-0.68; P < 0.01) and a large effect on pain expectancy (SMD 1.11; 95% CI 0.49-2.04; P < 0.01). The type of observation (in-person vs videotaped) modulated the magnitude of placebo hypoalgesia/nocebo hyperalgesia ( P < 0.01), whereas placebo type did not ( P = 0.23). Finally, OL was more effective when observers' empathic concern (but no other empathy-related factors) was higher ( r = 0.14; 95% CI 0.01-0.27; P = 0.03). Overall, the meta-analysis demonstrates that OL can shape placebo hypoalgesia and nocebo hyperalgesia. More research is needed to identify predictors of these effects and to study them in clinical populations. In the future, OL could be an important tool to help maximize placebo hypoalgesia in clinical settings.
- Open Access
- 25 November 2022
- Published by Center for Open Science in OSF Preprints
Placebo hypoalgesia and nocebo hyperalgesia induced by observational learning may be difficult to disentangle in a laboratory setting
Observational learning (OBL) can evoke placebo hypoalgesia and nocebo hyperalgesia, however, these effects have rarely been systematically compared. Healthy participants (n=105) were randomised to: 1) placebo OBL, 2) nocebo OBL, or 3) a no-observation control group. During OBL, a videotaped model simulated pain relief or increase after a sham ointment was applied. Thermal pain was evoked on two arms (ointment, control) at baseline and post-OBL. A three-way interaction confirmed that OBL modulates pain: F(2,93)=6.08, p=.003, ηp2=.12. Pain increased after nocebo OBL, with a bigger increase for the ointment arm (both p≤.007). After placebo OBL, pain increased for the control arm only (p<.001). Expectations mediated these effects. That pain for the control stimuli increased after placebo OBL could reflect nocebo learning. Experimental paradigms typically examine relative differences between ointment and control stimuli. Our results show that this can complicate disentangling placebo hypoalgesia and nocebo hyperalgesia in laboratory settings.
- 25 November 2022
- Published by Center for Open Science in OSF Preprints
Open AccessPlacebo hypoalgesia and nocebo hyperalgesia induced by observational learning may be difficult to disentangle in a laboratory setting
Observational learning (OBL) can evoke placebo hypoalgesia and nocebo hyperalgesia, however, these effects have rarely been systematically compared. Healthy participants (n=105) were randomised to: 1) placebo OBL, 2) nocebo OBL, or 3) a no-observation control group. During OBL, a videotaped model simulated pain relief or increase after a sham ointment was applied. Thermal pain was evoked on two arms (ointment, control) at baseline and post-OBL. A three-way interaction confirmed that OBL modulates pain: F(2,93)=6.08, p=.003, ηp2=.12. Pain increased after nocebo OBL, with a bigger increase for the ointment arm (both p≤.007). After placebo OBL, pain increased for the control arm only (p<.001). Expectations mediated these effects. That pain for the control stimuli increased after placebo OBL could reflect nocebo learning. Experimental paradigms typically examine relative differences between ointment and control stimuli. Our results show that this can complicate disentangling placebo hypoalgesia and nocebo hyperalgesia in laboratory settings.
- Open Access
- 26 July 2022
- Published by Center for Open Science in OSF Preprints
Learning pain from others: a systematic review and meta-analysis of studies on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning
Observing someone experience pain relief or exacerbation after an intervention may induce placebo hypoalgesia or nocebo hyperalgesia. Understanding which factors contribute to these effects could help in the development of strategies for optimizing treatment of chronic pain conditions. We systematically reviewed and meta-analyzed the literature on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning (OL). A systematic literature search was conducted in the databases PubMed, PsycINFO, Web of Science, ScienceDirect, PsycARTICLES, Scopus, and Academic Search Ultimate. 21 studies were included in the systematic review, 17 of which were suitable for meta-analysis (18 experiments; n=764 healthy individuals). The primary endpoint was the SMD for pain following placebo cues associated during OL with low versus high pain. OL had a small-to-medium effect on pain ratings (SMD 0.44; 95%CI 0.21 to 0.68; p<.01) and a large effect on pain expectancy (SMD 1.11; 95% CI 0.49 to 2.04; p<0.01). The type of observation (in-person vs. video) modulated the magnitude of placebo hypoalgesia/nocebo hyperalgesia (p<.01), whereas placebo type did not (p=.23). Finally, OL was more effective when observers’ empathic concern (but no other empathy-related factors) was higher (r=0.14; 95% CI 0.01 to 0.27; p=0.03). Overall, the meta-analysis demonstrates that OL can shape placebo analgesia and nocebo hyperalgesia. More research is needed to identify predictors of these effects and to study them in clinical populations. In the future, OL could be an important tool to help maximize placebo hypoalgesia in clinical settings.
- 26 July 2022
- Published by Center for Open Science in OSF Preprints
Open AccessLearning pain from others: a systematic review and meta-analysis of studies on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning
Observing someone experience pain relief or exacerbation after an intervention may induce placebo hypoalgesia or nocebo hyperalgesia. Understanding which factors contribute to these effects could help in the development of strategies for optimizing treatment of chronic pain conditions. We systematically reviewed and meta-analyzed the literature on placebo hypoalgesia and nocebo hyperalgesia induced by observational learning (OL). A systematic literature search was conducted in the databases PubMed, PsycINFO, Web of Science, ScienceDirect, PsycARTICLES, Scopus, and Academic Search Ultimate. 21 studies were included in the systematic review, 17 of which were suitable for meta-analysis (18 experiments; n=764 healthy individuals). The primary endpoint was the SMD for pain following placebo cues associated during OL with low versus high pain. OL had a small-to-medium effect on pain ratings (SMD 0.44; 95%CI 0.21 to 0.68; p<.01) and a large effect on pain expectancy (SMD 1.11; 95% CI 0.49 to 2.04; p<0.01). The type of observation (in-person vs. video) modulated the magnitude of placebo hypoalgesia/nocebo hyperalgesia (p<.01), whereas placebo type did not (p=.23). Finally, OL was more effective when observers’ empathic concern (but no other empathy-related factors) was higher (r=0.14; 95% CI 0.01 to 0.27; p=0.03). Overall, the meta-analysis demonstrates that OL can shape placebo analgesia and nocebo hyperalgesia. More research is needed to identify predictors of these effects and to study them in clinical populations. In the future, OL could be an important tool to help maximize placebo hypoalgesia in clinical settings.
- Open Access
- 8 July 2022
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-16
Risk and benefit for umbrella trials in oncology: a systematic review and meta-analysis
Background: Umbrella clinical trials in precision oncology are designed to tailor therapies to the specific genetic changes within a tumor. Little is known about the risk/benefit ratio for umbrella clinical trials. The aim of our systematic review with meta-analysis was to evaluate the efficacy and safety profiles in cancer umbrella trials testing targeted drugs or a combination of targeted therapy with chemotherapy. Methods: Our study was prospectively registered in PROSPERO (CRD42020171494). We searched Embase and PubMed for cancer umbrella trials testing targeted agents or a combination of targeted therapies with chemotherapy. We included solid tumor studies published between 1 January 2006 and 7 October 2019. We measured the risk using drug-related grade 3 or higher adverse events (AEs), and the benefit by objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). When possible, data were meta-analyzed. Results: Of the 6207 records identified, we included 31 sub-trials or arms of nine umbrella trials (N = 1637). The pooled overall ORR was 17.7% (95% confidence interval [CI] 9.5–25.9). The ORR for targeted therapies in the experimental arms was significantly lower than the ORR for a combination of targeted therapy drugs with chemotherapy: 13.3% vs 39.0%; p = 0.005. The median PFS was 2.4 months (95% CI 1.9–2.9), and the median OS was 7.1 months (95% CI 6.1–8.4). The overall drug-related death rate (drug-related grade 5 AEs rate) was 0.8% (95% CI 0.3–1.4), and the average drug-related grade 3/4 AE rate per person was 0.45 (95% CI 0.40–0.50). Conclusions: Our findings suggest that, on average, one in five cancer patients in umbrella trials published between 1 January 2006 and 7 October 2019 responded to a given therapy, while one in 125 died due to drug toxicity. Our findings do not support the expectation of increased patient benefit in cancer umbrella trials. Further studies should investigate whether umbrella trial design and the precision oncology approach improve patient outcomes.
- 8 July 2022
- Published by Springer Nature in BMC Medicine
- Vol. 20 (1) , 1-16
Open AccessRisk and benefit for umbrella trials in oncology: a systematic review and meta-analysis
Background: Umbrella clinical trials in precision oncology are designed to tailor therapies to the specific genetic changes within a tumor. Little is known about the risk/benefit ratio for umbrella clinical trials. The aim of our systematic review with meta-analysis was to evaluate the efficacy and safety profiles in cancer umbrella trials testing targeted drugs or a combination of targeted therapy with chemotherapy. Methods: Our study was prospectively registered in PROSPERO (CRD42020171494). We searched Embase and PubMed for cancer umbrella trials testing targeted agents or a combination of targeted therapies with chemotherapy. We included solid tumor studies published between 1 January 2006 and 7 October 2019. We measured the risk using drug-related grade 3 or higher adverse events (AEs), and the benefit by objective response rate (ORR), progression-free survival (PFS), and overall survival (OS). When possible, data were meta-analyzed. Results: Of the 6207 records identified, we included 31 sub-trials or arms of nine umbrella trials (N = 1637). The pooled overall ORR was 17.7% (95% confidence interval [CI] 9.5–25.9). The ORR for targeted therapies in the experimental arms was significantly lower than the ORR for a combination of targeted therapy drugs with chemotherapy: 13.3% vs 39.0%; p = 0.005. The median PFS was 2.4 months (95% CI 1.9–2.9), and the median OS was 7.1 months (95% CI 6.1–8.4). The overall drug-related death rate (drug-related grade 5 AEs rate) was 0.8% (95% CI 0.3–1.4), and the average drug-related grade 3/4 AE rate per person was 0.45 (95% CI 0.40–0.50). Conclusions: Our findings suggest that, on average, one in five cancer patients in umbrella trials published between 1 January 2006 and 7 October 2019 responded to a given therapy, while one in 125 died due to drug toxicity. Our findings do not support the expectation of increased patient benefit in cancer umbrella trials. Further studies should investigate whether umbrella trial design and the precision oncology approach improve patient outcomes.
- Open Access
- 10 June 2021
- Published by Springer Nature in Targeted Oncology
- Vol. 16 (4) , 415-424
Risk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
Background For research with human participants to be ethical, risk must be in a favorable balance with potential benefits. Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies. Objective Our aim was to conduct a systematic review of preliminary efficacy and safety profiles of phase II targeted therapy clinical trials in pediatric oncology. Methods Our protocol was prospectively registered in PROSPERO (CRD42020146491). We searched EMBASE and PubMed for phase II pediatric cancer trials testing targeted agents. We included solid and hematological malignancy studies published between 1 January, 2015 and 27 February, 2020. We measured risk using drug-related grade 3 or higher adverse events, and benefit by response rates. When possible, data were meta-analyzed. All statistical tests were two-sided. Results We identified 34 clinical trials (1202 patients) that met our eligibility criteria. The pooled overall response rate was 24.4% (95% confidence interval [CI] 14.5–34.2) and was lower in solid tumors, 6.4% (95% CI 3.2–9.6), compared with hematological malignancies, 55.1% (95% CI 35.9–74.3); p < 0.001. The overall fatal drug-related (grade 5) adverse event rate was 1.6% (95% CI 0.6–2.5), and the average drug-related grade 3/4 adverse event rate per person was 0.66 (95% CI 0.55–0.78). Conclusions We provide an estimate for the risks and benefits of participation in pediatric phase II cancer trials. These data may be used as an empirical basis for informed communication about benefits and burdens in pediatric oncology research.
- 10 June 2021
- Published by Springer Nature in Targeted Oncology
- Vol. 16 (4) , 415-424
Open AccessRisk and Benefit for Targeted Therapy Agents in Pediatric Phase II Trials in Oncology: A Systematic Review with a Meta-Analysis
Background For research with human participants to be ethical, risk must be in a favorable balance with potential benefits. Little is known about the risk/benefit ratio for pediatric cancer phase II trials testing targeted therapies. Objective Our aim was to conduct a systematic review of preliminary efficacy and safety profiles of phase II targeted therapy clinical trials in pediatric oncology. Methods Our protocol was prospectively registered in PROSPERO (CRD42020146491). We searched EMBASE and PubMed for phase II pediatric cancer trials testing targeted agents. We included solid and hematological malignancy studies published between 1 January, 2015 and 27 February, 2020. We measured risk using drug-related grade 3 or higher adverse events, and benefit by response rates. When possible, data were meta-analyzed. All statistical tests were two-sided. Results We identified 34 clinical trials (1202 patients) that met our eligibility criteria. The pooled overall response rate was 24.4% (95% confidence interval [CI] 14.5–34.2) and was lower in solid tumors, 6.4% (95% CI 3.2–9.6), compared with hematological malignancies, 55.1% (95% CI 35.9–74.3); p < 0.001. The overall fatal drug-related (grade 5) adverse event rate was 1.6% (95% CI 0.6–2.5), and the average drug-related grade 3/4 adverse event rate per person was 0.66 (95% CI 0.55–0.78). Conclusions We provide an estimate for the risks and benefits of participation in pediatric phase II cancer trials. These data may be used as an empirical basis for informed communication about benefits and burdens in pediatric oncology research.
- Open Access
- 24 June 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234911
Clinical development success rates and social value of pediatric Phase 1 trials in oncology
Drug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrogates of social value of Phase 1 trials performed in pediatric oncology: rates of approval of tested interventions, transition to further phases of testing and citation in subsequent primary research reports. We performed an analysis on a subset of eligible trials included in a previous meta-analysis. That study systematically searched EMBASE and PubMed for small sample size, non-randomized, dose escalation pediatric cancer Phase 1 studies of any malignancy, assessing chemotherapy and/or targeted therapy and looked at risk and benefit. The current analysis assessed all studies in that review published between January 1st 2004 and December 31st 2013 for predictors of social value. This time range allowed for at least five years of subsequent development activity. Sources of data included FDA and EMA medicine databases (for approval), ClinicalTrials.gov and EU Clinical Trials Register (for transition) and Google Scholar (for citation). One hundred thirty-nine trials enrolling 3814 patients met the eligibility criteria. Seven trials (5%) led to drugs being registered for pediatric use in therapy of cancer. Fifty-two (37%) transitioned to later phases of pediatric oncology trials according to ClinicalTrials.gov and/or EU Register. Over 90% of trials were cited by at least one subsequent primary research report or systematic review. Most of the citations were preclinical studies. Our analysis shows that treatments tested in pediatric Phase 1 trials in oncology have low rates of regulatory approval. However, a large proportion of Phase 1 trials inform further testing and development of tested interventions.
- 24 June 2020
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 15 (6) , e0234911
Open AccessClinical development success rates and social value of pediatric Phase 1 trials in oncology
Drug development trials must fulfill social value requirement but no estimates of value provided by pediatric Phase 1 trials in oncology exist. These trials involve a particularly vulnerable population. Our objective was to assess of surrogates of social value of Phase 1 trials performed in pediatric oncology: rates of approval of tested interventions, transition to further phases of testing and citation in subsequent primary research reports. We performed an analysis on a subset of eligible trials included in a previous meta-analysis. That study systematically searched EMBASE and PubMed for small sample size, non-randomized, dose escalation pediatric cancer Phase 1 studies of any malignancy, assessing chemotherapy and/or targeted therapy and looked at risk and benefit. The current analysis assessed all studies in that review published between January 1st 2004 and December 31st 2013 for predictors of social value. This time range allowed for at least five years of subsequent development activity. Sources of data included FDA and EMA medicine databases (for approval), ClinicalTrials.gov and EU Clinical Trials Register (for transition) and Google Scholar (for citation). One hundred thirty-nine trials enrolling 3814 patients met the eligibility criteria. Seven trials (5%) led to drugs being registered for pediatric use in therapy of cancer. Fifty-two (37%) transitioned to later phases of pediatric oncology trials according to ClinicalTrials.gov and/or EU Register. Over 90% of trials were cited by at least one subsequent primary research report or systematic review. Most of the citations were preclinical studies. Our analysis shows that treatments tested in pediatric Phase 1 trials in oncology have low rates of regulatory approval. However, a large proportion of Phase 1 trials inform further testing and development of tested interventions.
- Open Access
Results dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis
Objectives To establish the rates of publication and reporting of results for interventional clinical trials across Polish academic medical centres (AMCs) completed between 2009 and 2013. We aim also to compare the publication and reporting success between adult and paediatric trials. Design Cross-sectional study. Setting AMCs in Poland. Participants AMCs with interventional trials registered on ClinicalTrials.gov. Main outcome measure Results reporting on ClinicalTrials.gov and publishing via journal publication. Results We identified 305 interventional clinical trials registered on ClinicalTrials.gov, completed between 2009 and 2013 and affiliated with at least one AMC. Overall, 243 of the 305 trials (79.7%) had been published as articles or posted their summary results on ClinicalTrials.gov. Results were posted within a year of study completion and/or published within 2 years of study completion for 131 trials (43.0%). Dissemination by both posting and publishing results in a timely manner was achieved by four trials (1.3%). Conclusions Our cross-sectional analysis revealed that Polish AMCs fail to meet the expectation for timely disseminating the findings of all interventional clinical trials. Delayed dissemination and non-dissemination of trial results negatively affects decisions in healthcare.
Open AccessResults dissemination of registered clinical trials across Polish academic institutions: a cross-sectional analysis
Objectives To establish the rates of publication and reporting of results for interventional clinical trials across Polish academic medical centres (AMCs) completed between 2009 and 2013. We aim also to compare the publication and reporting success between adult and paediatric trials. Design Cross-sectional study. Setting AMCs in Poland. Participants AMCs with interventional trials registered on ClinicalTrials.gov. Main outcome measure Results reporting on ClinicalTrials.gov and publishing via journal publication. Results We identified 305 interventional clinical trials registered on ClinicalTrials.gov, completed between 2009 and 2013 and affiliated with at least one AMC. Overall, 243 of the 305 trials (79.7%) had been published as articles or posted their summary results on ClinicalTrials.gov. Results were posted within a year of study completion and/or published within 2 years of study completion for 131 trials (43.0%). Dissemination by both posting and publishing results in a timely manner was achieved by four trials (1.3%). Conclusions Our cross-sectional analysis revealed that Polish AMCs fail to meet the expectation for timely disseminating the findings of all interventional clinical trials. Delayed dissemination and non-dissemination of trial results negatively affects decisions in healthcare.